US Patent

US7612058 — Methods for inhibiting sterol absorption

Method of Use · Assigned to Schering Corp · Expires 2025-10-30 · 1y expired

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating vascular conditions, diabetes, obesity, and lowering plasma sterol levels using a combination of a peroxisome proliferator-activated receptor activator and a sterol absorption inhibitor.

USPTO Abstract

The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted beta-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

Drugs covered by this patent

Zetia (EZETIMIBE) · Merck & Co.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1173`	—	Zetia

Patent Metadata

Patent number: US7612058
Jurisdiction: US
Classification: Method of Use
Expires: 2025-10-30
Drug substance claim: No
Drug product claim: No
Assignee: Schering Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.